Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auxora in Acute Pancreatitis and SIRS
NCT04681066Phase 2Completed
- Sponsor
- CalciMedica
- Start
- Mar 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of Auxora in acute pancreatitis (AP) and Systemic Inflammatory Response Syndrome (SIRS) (4 arms), sponsored by CalciMedica. Primary endpoint: Median Time to Solid Food Tolerance up to 30 days. Started Mar 2021; status: completed.
02
Drugs
Auxora
03
Conditions
acute pancreatitis (AP)Systemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on NCT04681066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04681066.